Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24075745 | 0.94 | SLC6A2 (0.67) | SLC6A2SLC6A4KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL30301405 | 0.87 | SLC6A2 (0.71) | SLC6A2SLC6A4KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL27015989 | 0.87 | SLC6A2 (0.71) | SLC6A2SLC6A4KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL27015752 | 0.86 | SLC6A2 (0.70) | SLC6A2SLC6A4KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL30301396 | 0.86 | SLC6A2 (0.70) | SLC6A2SLC6A4KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL27015546 | 0.86 | SLC6A2 (0.70) | SLC6A2SLC6A4KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL30301376 | 0.86 | SLC6A2 (0.70) | SLC6A2SLC6A4KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL27016437 | 0.86 | SLC6A2 (0.89) | SLC6A2SLC6A4KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL27008240 | 0.84 | SLC6A2 (0.73) | SLC6A2SLC6A4KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL30301407 | 0.84 | ACHE (0.75) | SLC6A2SLC6A4KDM4EACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2024-01-18 | — | — | US | disclosed |
| WO-2021241876-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | 재단법인 대구경북첨단의료산업진흥재단 | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | MAOA, DRD2, MAOB | SLC6A2 4/4885SLC6A4 23/4885KDM4E 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.